Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Prospective Survey of β-Lactamases Produced by Ceftazidime- Resistant Pseudomonas aeruginosa Isolated in a French Hospital in 2000

Christophe De Champs, Laurent Poirel, Richard Bonnet, Danielle Sirot, Catherine Chanal, Jacques Sirot, Patrice Nordmann
Christophe De Champs
1Service de Bactériologie, Faculté de Médecine, Université d'Auvergne, 63001 Clermont-Ferrand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christophe.dechamps@u-clermont1.fr
Laurent Poirel
2Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, 94275 Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Bonnet
1Service de Bactériologie, Faculté de Médecine, Université d'Auvergne, 63001 Clermont-Ferrand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle Sirot
1Service de Bactériologie, Faculté de Médecine, Université d'Auvergne, 63001 Clermont-Ferrand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Chanal
1Service de Bactériologie, Faculté de Médecine, Université d'Auvergne, 63001 Clermont-Ferrand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Sirot
1Service de Bactériologie, Faculté de Médecine, Université d'Auvergne, 63001 Clermont-Ferrand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Nordmann
2Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, 94275 Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.46.9.3031-3034.2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In 2000, at the Université d'Auvergne teaching hospital in Clermont-Ferrand, France, 44 (6.2%) strains of Pseudomonas aeruginosa were found to be resistant to ceftazidime. After genotyping, 34 strains were selected. Nine had an additional β-lactamase: OXA-21 (n = 6), PSE-1 (CARB-2) (n = 2), or PER-1 (n = 1). Ceftazidime resistance was related solely to the overproduction of the cephalosporinase in 30 strains. Sequencing of five blaAmpC genes encoding cephalosporinases with different pIs showed 99% identity with the ampC gene of P. aeruginosa PAO1.

Resistance to extended-spectrum cephalosporins in Pseudomonas aeruginosa is associated in most cases with the overproduction of a naturally produced cephalosporinase (19). Derepression of this AmpC β-lactamase affects all β-lactams to various extents, which may lead to the misdetection of other acquired β-lactamases. Enzymes hydrolyzing extended-spectrum cephalosporins of Ambler classes A, B, and D have been reported in P. aeruginosa (19). Among the extended-spectrum β-lactamases (ESBLs) of class A, TEM-4 (22), TEM-24 (15), TEM-42 (16), PER-1 (18), SHV-2a (19), VEB-1 (21), and GES-2 (26) have been encountered.

Class B enzymes, IMP-1 (33), VIM-1 (10), VIM-2 (23), and VIM-related enzymes (11), hydrolyze carbapenems in addition to extended-spectrum cephalosporins.

The extended-spectrum class D enzymes are OXA-2 derivatives (OXA-15 [4] and OXA-32 [24]), OXA-10 derivatives (OXA-11 [7], OXA-14 [3], OXA-16 [5], OXA-17 [6], OXA-19 [17], and OXA-28 [25]), and OXA-18 (20).

Other mechanisms implicated in resistance to β-lactams in P. aeruginosa are impermeability of the outer membrane and increased efflux (12) The aim of this study was to characterize the β-lactamases produced by ceftazidime-resistant P. aeruginosa isolates.

Of the 713 nonduplicate P. aeruginosa strains isolated from the Université d'Auvergne teaching hospital in Clermont-Ferrand, France, between 1 January and 30 September 2000, 44 (6.2%) were resistant to ceftazidime, as determined by the disk diffusion method on Mueller-Hinton agar according to the recommendations of the Antibiogram Committee of the French Society for Microbiology (zone diameter, <15 mm; www.sfm.asso.fr/Sect4/atbuk.html ). This prevalence of ceftazidime resistance was higher than the 4% prevalence in 1996 reported in a previous French national multicenter study (2). Isolates were identified with the ID 32 GN system (BioMérieux, Marcy l'Etoile, France). A duplicate isolate was defined as an isolate with the same antibiotic resistance phenotype as another isolate from the same patient during the same course of infection. The 44 strains were typed by random amplification of polymorphic DNA (RAPD) with two primers, ERIC-2 and 208, as described previously (Table 1) (14, 30). Isoelectric focusing analysis was performed with 6% polyacrylamide gels containing ampholines (Amersham Pharmacia Biotech, Uppsala, Sweden) with a pH range of 3.5 to 10, as reported previously (19). Among the 44 strains, 34 were selected on the basis of antibiotic resistance patterns, pIs, and patterns by RAPD analysis (Table 2). The chromosomal cephalosporinases focused at five pIs: 8.4 (n = 13), 8.0 (n = 8), 8.0 and 8.4 (n = 7), 7.8 (n = 4), and 8.6 (n = 2). Three additional β-lactamases were found at pIs 7.0 (n = 6), 5.7 (n = 2), and 5.4 (n = 1). The strains were distributed into 33 different RAPD profiles.

The MICs of drugs alone or in combination with a fixed concentration of clavulanate (2 μg/ml) and tazobactam (4 μg/ml) were determined by the dilution method in Mueller-Hinton agar with an inoculum of 104 CFU per spot, as described previously (20) (Table 2). The MICs of ceftazidime were in a narrow range from 32 to 128 μg/ml. The MICs of ticarcillin ranged from 64 to 2,048 μg/ml. The use of clavulanate did not restore susceptibility to ticarcillin. The MICs of piperacillin were between 16 and 256 μg/ml, and the MICs of aztreonam were between 16 and 128 μg/ml. The strains were moderately resistant to cefepime (MICs, 8 to 64 μg/ml). Fifteen strains were resistant to imipenem (MICs, >8 μg/ml), and of these, three were resistant to meropenem (MICs, >8 μg/ml).

Cephalosporinase inhibition, evaluated by the disk diffusion method on Mueller-Hinton agar containing cloxacillin at 250 or 500 μg/ml, was considered significant when the ceftazidime zone diameter increased by >10 mm. P. aeruginosa PAO1 was used as the reference strain (8). For 25 strains which did not have pI values that might correspond to those for an additional β-lactamase, ceftazidime activity was partially restored by cloxacillin at 250 μg/ml (n = 15) or only by cloxacillin at 500 μg/ml (n = 10). For these 25 strains without an additional β-lactamase, the level of production of the AmpC enzymes was measured by determination of their specific β-lactamase activities. Cultures were grown overnight at 37°C in 3 liters of brain heart infusion (Biokar Diagnostics, Beauvais, France). Bacterial suspensions were disrupted by sonication and centrifuged as described previously (19). The supernatants were dialyzed against 3 liters of 100 mM NaCl overnight at 4°C. Then, the specific β-lactamase activities of the crude extracts were determined by a computerized microacidimetric method described elsewhere (9) with 225 mM benzylpenicillin as the substrate. The total protein concentration in the enzyme preparation was estimated by a protein assay (Bio-Rad, Richmond, Calif.) with bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.) as the standard. One unit of specific β-lactamase activity was defined as the amount of enzyme which hydrolyzes 1 μmol of benzylpenicillin per min and per mg of protein at 37°C and at pH 7. For 21 strains the specific activity was 100- to 1,000-fold greater than that of PAO1, with values ranging from 124 to 15,373 mU mg−1 (Table 2). Variations in levels of resistance to ceftazidime were weakly related to different levels of enzyme overproduction (i.e., an MIC of 64 μg/ml corresponds to specific activities of 52 mU mg−1 for strain 33 and 15,373 mU mg−1 for strain 5).

The ampC genes of the strains that produced five cephalosporinases with different pI values were amplified with primers AMPC-PAC and AMPC-PAD (Table 1) under the following conditions: 94°C for 5 min and then 30 cycles of 94°C for 1 min, 50°C for 3 min, and 72°C for 3 min, with a single final extension at 72°C for 15 min. The PCR products were sequenced with the primers AMPC-PAD, AMPC-PAG, AMPC-28, and AMPC-PAB1 (Table 1). Sequence analysis showed a low level of sequence diversity (0.17 to 0.75%) and 99% nucleotide identity with the ampC gene of P. aeruginosa strain PAO1 (GenBank accession no. X54719 ). Compared to the PAO1 ampC gene sequence (8), all ampC genes encoding enzymes with pIs different from 8.0 harbored the mutation A866→G, which led to the substitution Thr105→Ala (Table 3).

Genes encoding enzymes of pI 8.0 + 8.4 and pI 8.4 harbored a mutation at position 1166 that led to the substitution Val205→Leu. The ampC gene encoding the enzyme of pI 7.8 harbored the mutation G789→A, which led to the substitution Arg79→Gln, and that encoding the enzyme of pI 8.6 harbored the mutation T1080→G, which led to the substitution Leu176→Arg. The Arg79→Gln substitution is associated with a change in charges and may have been responsible for the decrease in the pI value from 8.0 to 7.8, as reported previously (28). However, enzymes with identical pIs do not necessarily share identical amino acid sequences, and the different pIs suggested that some bands correspond to cleaved derivatives (isoenzymes) of the cephalosporinase, as reported previously (32).

For eight of the nine strains with an additional β-lactamase, ceftazidime activity was restored only by cloxacillin at 500 μg/ml (strains 18 to 25), and so ceftazidime resistance was very likely due to hydrolysis by the derepressed chromosomal cephalosporinase. For strain 4 the activity of ceftazidime was not restored by cloxacillin at 500 μg/ml. Strain 4 was the only one which had a positive modified disk synergy test result with ceftazidime and clavulanate (27). The genes of the six β-lactamases with a pI of 7.0 were amplified with OXA-2 primers (primers OXA-2,3 and OXB-2,3). Nucleotide sequence analysis of the blaOXA PCR products revealed a blaOXA-21 sequence with only one silent mutation (T697→C) in the genes of four isolates compared to the sequence of blaOXA-21 previously reported for Acinetobacter baumannii (31) (EMBL database accession no. Y10693 ). The six strains that produced OXA-21 had different RAPD patterns (data not shown). To our knowledge, this is the first report of OXA-21 in P. aeruginosa.

The blaPSE-1 gene was detected in two strains by PCR with primers OC1 and OC3 (Table 1), and a protein with a pI of 5.7 conferred a very high level of resistance to ticarcillin (MICs, >2,048 μg/ml) and ticarcillin-clavulanate (MICs, 256/1,024 μg/ml).

The blaPER-1 gene of the strain producing the β-lactamase with a pI of 5.4 was identified by PCR with primers PER-A and PER-B (Table 1) and sequencing. Epidemics caused by strains with this enzyme, previously reported in Turkey (29) and Italy (13), are now observed in France.

The carbapenem resistance observed in 15 strains was not related to enzymatic hydrolysis by a carbapenem-hydrolyzing β-lactamase. Although several ESBLs were reported in P. aeruginosa, their prevalences were very low in our study.

View this table:
  • View inline
  • View popup
TABLE 1.

Oligonucleotides used as primers for amplification and/or sequencing

View this table:
  • View inline
  • View popup
TABLE 2.

Characteristics of the 34 ceftazidime-resistant P. aeruginosa isolates

View this table:
  • View inline
  • View popup
TABLE 3.

Substitution in blaAmpC genes according to the pI value for each cephalosporinase and comparison with the sequence of the blaAmpC gene of P. aeruginosa strain PAO1 (pI 8.0)

ACKNOWLEDGMENTS

We thank Rolande Perroux, Marlène Jan, and Dominique Rubio for technical assistance. We are also grateful to J. Watts for reading the English manuscript.

This work was supported in part by a grant from the Ministère de l'Education Nationale, de la Recherche et de la Technologie.

FOOTNOTES

    • Received 24 October 2001.
    • Returned for modification 7 February 2002.
    • Accepted 14 May 2002.
  • Copyright © 2002 American Society for Microbiology

REFERENCES

  1. 1.
    Arlet, G., and A. Philippon. 1991. Construction by polymerase chain reaction and intragenic DNA probes for three main types of transferable β-lactamases (TEM, SHV, CARB). FEMS Microbiol. Lett.82:19-26.
    OpenUrlCrossRef
  2. 2.↵
    Cavallo, J. D., R. Fabre, F. Leblanc, M. H. Nicolas-Chanoine, A. Thabaut, and the GERPB. 2000. Antibiotic susceptibility and mechanisms of β-lactam resistance in 1310 strains of Pseudomonas aeruginosa: a French multicentre study (1996). J. Antimicrob. Chemother.46:133-136.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Danel, F., L. M. C. Hall, D. Gur, and D. M. Livermore. 1995. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother.39:1881-1884.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Danel, F., M. Lucinda, C. Hall, D. Gur, and D. M. Livermore. 1997. OXA-15, an extended-spectrum variant of OXA-2 β-lactamase isolated from a Pseudomonas aeruginosa strain. Antimicrob. Agents Chemother.41:785-790.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Danel, F., L. M. Hall, D. Gur, and D. M. Livermore. 1998. OXA-16, a further extended-spectrum variant of OXA-10 β-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob. Agents Chemother.42:3117-3122.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Danel, F., L. M. Hall, B. Duke, D. Gur, and D. M. Livermore. 1999. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa.Antimicrob. Agents Chemother.43:1362-1366.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Hall, L. M. C., D. M. Livermore, D. Gur, M. Akova, and H. E. Akalin. 1993. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa.Antimicrob. Agents Chemother.37:1637-1644.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Kiewitz, C., and B. Tümmler. 2000. Sequence diversity of Pseudomonas aeruginosa: impact on population structure and genome evolution. J. Bacteriol.182:3125-3135.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Labia, R., J. Andrillon, and F. Le Goffic. 1973. Computerized microacidimetric determination of β-lactamase Michaelis-Menten constants. FEBS Lett.33:42-44.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Lauretti, L., M. L. Riccio, A. Mazzariol, G. Cornaglia, G. Amicosante, R. Fontana, and G. M. Rossolini. 1999. Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother.43:1584-1590.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Livermore, D. M., and N. Woodford. 2000. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol.3:489-495.D. M.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Livermore, D. M. 2001. Of Pseudomonas, porins pumps and carbapenems. J. Antimicrob. Chemother.47:247-250.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Luzzaro, F., E. Mantengoli, M. Perilli, G. Lombardi, V. Orlandi, A. Orsatti, G. Amicosante, G. M. Rossolini, and A. Toniolo. 2001. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J. Clin. Microbiol.39:1865-1870.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Mahenthiralingam, E., M. E. Campbell, J. Foster, J. S. Lam, and D. P. Speert. 1996. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J. Clin. Microbiol.34:1129-1135.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Marchandin, H., H. Jean-Pierre, C. De Champs, D. Sirot, H. Darbas, P. F. Perigault, and C. Carriere. 2000. Production of a TEM-24 plasmid-mediated extended-spectrum β-lactamase by a clinical isolate of Pseudomonas aeruginosa.Antimicrob. Agents Chemother.44:213-216.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Mugnier, P., P. Dubrous, I. Casin, G. Arlet, and E. Collatz. 1996. A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa.Antimicrob. Agents Chemother.40:2488-2493.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Mugnier, P., I. Casin, A. T. Bouthors, and E. Collatz. 1998. Novel OXA-10-derived extended-spectrum β-lactamases selected in vivo or in vitro. Antimicrob. Agents Chemother.42:3113-3116.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Nordmann, P., E. Ronco, T. Naas, C. Duport, Y. Michel-Briand, and R. Labia. 1993. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa.Antimicrob. Agents Chemother.37:962-969.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Nordmann, P., and M. Guibert. 1998. Extended-spectrum β-lactamases in Pseudomonas aeruginosa. J. Antimicrob. Chemother.42:128-131.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Philippon, L. N., T. Naas, A. T. Bouthors, V. Barakett, and P. Nordmann. 1997. OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa.Antimicrob. Agents Chemother.41:2188-2195.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Poirel, L., T. Naas, M. Guibert, E. B. Chaibi, R. Labia, and P. Nordmann. 1999. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum beta-lactamase encoded by an Escherichia coli integron gene. Antimicrob. Agents Chemother.43:573-581.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Poirel, L., E. Ronco, T. Naas, and P. Nordmann. 1999. Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa.Clin. Microbiol. Infect.5:651-652.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Poirel, L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J. D. Cavallo, and P. Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother.44:891-897.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    Poirel, L., P. Gerome, C. De Champs, J. Stephanazzi, and P. Nordmann. 2002. Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa.Antimicrob. Agents Chemother.46:566-569.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    Poirel, L., D. Girlich, T. Naas, and P. Nordmann. 2001. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob. Agents Chemother.45:447-453.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    Poirel, L., G. F. Weldhagen, T. Naas, C. De Champs, M. G. Dove, and P. Nordmann. 2001. Characterization of the class A β-lactamase GES-2 from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob. Agents Chemother.45:2965-2968.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    Sirot, J. 1996. Detection of extended-spectrum plasmid-mediated β-lactamases by disk diffusion. Clin. Microbiol. Infect.2(Suppl. 1):35-39.
    OpenUrlCrossRef
  28. 28.↵
    Spangenberg, C., T. C. Montie, and B. Tümmler. 1998. Structural and functional implications of sequence diversity of Pseudomonas aeruginosa genes oriC,ampC and fliC.Electrophoresis19:545-550.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Vahaboglu, H., R. Oztürk, G. Aygün, F. Coskunkan, A. Yaman, A. Kaygusuk, H. Leblebicioglu, I. Balik, K. Aydin, and M. Otkun. 1997. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob. Agents Chemother.41:2265-2269.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Versalovic, J., T. Koeuth, and J. R. Lupski. 1991. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res.19:6823-6831.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    Vila, J., M. Navia, J. Ruiz, and C. Casals. 1997. Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived β-lactamase in Acinetobacter baumannii.Antimicrob. Agents Chemother.41:2757-2759.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    Walther-Rasmussen, J., A. H. Johnsen, and N. Hoiby. 1999. Terminal truncations in AmpC β-lactamase from a clinical isolate of Pseudomonas aeruginosa.Eur. J. Biochem.263:478-485.
    OpenUrlPubMed
  33. 33.↵
    Watanabe, M., S. Iyobe, M. Inoue, and S. Mitsuhashi. 1991. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.35:147-151.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Prospective Survey of β-Lactamases Produced by Ceftazidime- Resistant Pseudomonas aeruginosa Isolated in a French Hospital in 2000
Christophe De Champs, Laurent Poirel, Richard Bonnet, Danielle Sirot, Catherine Chanal, Jacques Sirot, Patrice Nordmann
Antimicrobial Agents and Chemotherapy Sep 2002, 46 (9) 3031-3034; DOI: 10.1128/AAC.46.9.3031-3034.2002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prospective Survey of β-Lactamases Produced by Ceftazidime- Resistant Pseudomonas aeruginosa Isolated in a French Hospital in 2000
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prospective Survey of β-Lactamases Produced by Ceftazidime- Resistant Pseudomonas aeruginosa Isolated in a French Hospital in 2000
Christophe De Champs, Laurent Poirel, Richard Bonnet, Danielle Sirot, Catherine Chanal, Jacques Sirot, Patrice Nordmann
Antimicrobial Agents and Chemotherapy Sep 2002, 46 (9) 3031-3034; DOI: 10.1128/AAC.46.9.3031-3034.2002
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

ceftazidime
cephalosporins
Pseudomonas Infections
Pseudomonas aeruginosa
beta-lactamases

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596